Community Academic Profiles

Jennifer Hoblyn

Publication Details

  • Acetylcholinesterase inhibitor in combination with cognitive training in older adults.

    Yesavage JA, Friedman L, Ashford JW, Kraemer HC, Mumenthaler MS, Noda A, Hoblyn J. J Gerontol B Psychol Sci Soc Sci. 2008; 63 (5): P288-94

    To determine if donepezil, an acetylcholinesterase (AChE) inhibitor, improved the assimilation of cognitive training by older adults with memory complaints, we gave 168 nondemented, community-dwelling volunteers with memory complaints either 5 mg of donepezil (Aricept) or placebo daily for 6 weeks in a randomized, double-blind, placebo-controlled trial. The dosage rose to 10 mg daily for another 6 weeks before a 2-week course of cognitive training and was maintained for the remainder of a year. Cognitive training improved performance; donepezil was well tolerated. However, there were no significant benefits of donepezil compared with placebo. An additional dose-ranging study with a starting dose of 5 mg a day suggests that the high dose was not the reason. Physiological tolerance may occur with chronic donepezil treatment and may increase AChE levels; this may be why short-term studies have shown the benefit of AChE inhibitor use in nondemented participants whereas chronic use has failed to enhance cognition.

    PubMedID: 18818443

Stanford Medicine Resources:

Footer Links: